Stockscreener 앱 받기
0.0123
17.09%
-0.00253
전일 마감가:
$0.0148
열려 있는:
$0.015
하루 거래량:
105.02K
Relative Volume:
1.73
시가총액:
$N/A
수익:
$7.33M
순이익/손실:
$-21.20M
주가수익비율:
-0.0134
EPS:
-0.9143
순현금흐름:
$-12.68M
1주 성능:
-39.36%
1개월 성능:
-59.17%
6개월 성능:
-86.39%
1년 성능:
-96.64%
1일 변동 폭
$0.0123
$0.0159
1주일 범위
$0.0123
$0.0159
52주 변동 폭
$0.0123
$0.1199
프로페이즈 Stock (PRPH) Company Profile
Compare PRPH vs TMO, DHR, NTRA, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRPH
Prophase Labs Inc
|
0.0123 | 0 | 7.33M | -21.20M | -12.68M | -0.9143 |
TMO
Thermo Fisher Scientific Inc
|
651.45 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
211.81 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
369.39 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
156.47 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
266.42 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
프로페이즈 Stock (PRPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-20 | 개시 | H.C. Wainwright | Buy |
| 2021-10-13 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2021-01-20 | 개시 | Dawson James | Buy |
프로페이즈 주식(PRPH)의 최신 뉴스
ProPhase Labs stock trades quietly as investors look to recent diagnostics performance - ad-hoc-news.de
ProPhase Labs Flags Going Concern Risk as Q2 Loss Widens - Minichart
ProPhase Labs, Inc. Q2 2026: Revenue $1.01M, EPS $(0.22) — 10-Q Summary - TradingView
ProPhase Labs (NASDAQ: PRPH) flags going‑concern risk as cash runs low - Stock Titan
ProPhase Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProPhase Labs Delays Quarterly SEC Filing - TipRanks
ProPhase Labs (PRPH) cites auditor review delays for late Q2 2026 10-Q filing - Stock Titan
ProPhase Labs Secures Convertible Loan to Strengthen Liquidity - TipRanks
ProPhase Labs enters senior secured convertible loan agreement with J.J. Astor & Co for $2.09 million principal amount - Bitget
ProPhase Labs, Inc. Revenue Breakdown – OTC:PRPH - TradingView
ProPhase Units Strike Tentative Deal To Avert Ch. 7 Push - Law360
ProPhase Labs Restates Q1 2026 Financials: Key Changes and Impact Explained in Amended 10-Q/A - Minichart
ProPhase Labs (NASDAQ: PRPH) restates Q1 2026 and discloses going concern risk - Stock Titan
ProPhase Labs Inc updates its health portfolio as ProPhase Labs stock trades on Nasdaq - Ad-hoc-news.de
ProPhase Labs Inc explores growth opportunities in diagnostics and consumer health - Ad-hoc-news.de
ProPhase Labs (PRPH) Q1 2026 loss, equity deficit and going‑concern risk - Stock Titan
ProPhase Labs, Inc. (PRPH) Q1 2026 10-Q: Financials, Stock Info, and Key SEC Filing Details - minichart.com.sg
ProPhase Labs, Inc. 1Q 2026: Revenue $478K, EPS $(0.43) — 10-Q Summary - TradingView
ProPhase Labs (PRPH) flags going concern risk after Q1 2026 loss and heavy financing - Stock Titan
ProPhase Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PRPH: Net loss widened to $5.4 million amid revenue decline and ongoing liquidity challenges - TradingView
Price to sales forward of ProPhase Labs, Inc. – OTC:PRPH - TradingView
Enterprise value to EBITDA forward of ProPhase Labs, Inc. – OTC:PRPH - TradingView
ProPhase Labs, Inc. Actuals & Estimates (OTC:PRPH) - TradingView
Prophase Labs Inc (PRPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProPhase Labs StockLong-term business model and market position - AD HOC NEWS
Prophase Labs Inc (PRPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prophase Labs Inc (PRPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Prophase Labs Inc (PRPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prophase Labs Inc (PRPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prophase Labs Inc (PRPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProPhase Labs, Inc. 2025 Annual Report: Genomics, Biotech, Diagnostics, and Supplement Innovations Overview - Minichart
ProPhase Labs, Inc. FY 2025: Revenue $4.35M, EPS ($1.74) — 10-K Summary - TradingView
[10-K] ProPhase Labs, Inc. Files Annual Report - Stock Titan
ProPhase Labs, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
MSN Money - MSN
PRPH | PROPHASE LABS INC Insider Trading - Quiver Quantitative
ProPhase Labs stock (US74345W1080): earnings update and shifting focus beyond COVID testing - AD HOC NEWS
ProPhase Labs Delays Quarterly Financial Filing - TipRanks
ProPhase Labs (NASDAQ: PRPH) delays Q1 2026 10-Q amid 2025 audit - Stock Titan
ProPhase Labs stock (US74345W1080): Reverse stock split raises questions - AD HOC NEWS
TradingKey - TradingKey
Prophase Labs Stock Price Forecast. Should You Buy PRPH? - StockInvest.us
ProPhase Testing Units Creditor Says No Real Ch. 11 Progress - Law360
PROPHASE LABS INC by ProPhase Labs, Inc. Analyst Ratings and Price Targets | OTC:PRPH - Benzinga
ProPhase Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProPhase Labs earnings missed by $2.47, revenue fell short of estimates - Investing.com Canada
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform - The Manila Times
Geopolitics Watch: What analysts say about ProPhase Labs Inc stock2026 Gainers & Target Return Focused Stock Picks - baoquankhu1.vn
ETF Watch: Is ProPhase Labs Inc exposed to political riskMarket Movement Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Street Watch: Is ProPhase Labs Inc exposed to currency risksRate Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
프로페이즈 (PRPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
1.02%
자본화:
|
볼륨(24시간):